Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ceo.14142 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning-based personalized prediction of sperm retrieval in patients with non-obstructive azoospermia prior to microdissection testicular sperm extraction: A multi-center cohort study.
Andrology
September 2025
Department of Urology, Peking University First Hospital, Beijing, China.
Background: Non-obstructive azoospermia represents the most severe form of male infertility. The heterogeneous nature of focal spermatogenesis within the testes of non-obstructive azoospermia patients poses significant challenges for accurately predicting sperm retrieval rates.
Objectives: To develop a machine learning-based predictive model for estimating sperm retrieval rates in patients with non-obstructive azoospermia.
Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report.
Cancer Rep (Hoboken)
September 2025
Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Background: Cancer of unknown primary (CUP) is a challenging malignancy characterized by metastatic tumors with an unidentified primary site, even after extensive pathological and radiographic evaluation. Recent advancements in gene expression profiling and comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) have enabled the identification of potential tissue origins, thereby facilitating personalized treatment strategies. Although most cases of CUP present as adenocarcinomas or poorly differentiated tumors, the treatment remains largely empirical, with limited success from molecularly tailored therapies.
View Article and Find Full Text PDFInsights Into Kaposi Sarcoma-Associated Herpesvirus-Specific Humoral Responses.
J Med Virol
September 2025
Department of Interdisciplinary Oncology, School of Medicine, Stanley S. Scott Cancer Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Kaposi sarcoma (KS) remains a global health concern. In sub-Saharan Africa, where there is a high burden of HIV-1 infection, there is also a high prevalence of infection by the etiologic agent of KS, the KS-associated herpesvirus (KSHV). Despite the successes of antiretroviral treatment (ART), the burden of KS and other KSHV-associated malignancies among people living with HIV under ART remained high, stressing the need for a greater understanding of the immune response against KSHV infection.
View Article and Find Full Text PDFThe efficacy of a hunger-induced two-week tube-weaning program: a retrospective study.
Croat Med J
August 2025
Sara Sila, Department of Pediatrics, Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Klaićeva 16, 10000 Zagreb, Croatia,
Aim: To assess the efficacy of a multidisciplinary tube-weaning program.
Methods: This retrospective cohort study enrolled children with feeding tube dependency who had not responded to standard tube-weaning interventions. All participants underwent a structured two-week multidisciplinary tube weaning delivered in a day-hospital setting at the Children's Hospital Zagreb in the period from August 2016 to February 2023.
Advances in Gene Therapy Clinical Trials for Hemophilia Care.
Curr Gene Ther
September 2025
Centre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
Gene therapy has revolutionized the therapeutic landscape for hemophilia A and B, offering the prospect for persistent endogenous production of coagulation factors VIII and IX. Recent advances in adeno-associated virus (AAV)-mediated gene transfer, particularly the approvals of valoctocogene roxaparvovec (Roctavian) and etranacogene dezaparvovec (Hemgenix), mark significant milestones in hemophilia care. This mini-review synthesizes emerging clinical data from phase I-III trials published between 2022 and 2025, emphasizing efficacy, durability, and immunogenicity profiles of leading AAV-based therapies.
View Article and Find Full Text PDF